A knowledge of the new agents, their unique toxicity profiles and their impact on prognosis will improve the care of sufferers with advanced melanoma in primary care.. Advanced melanoma: the changing landscape of treatment Recently developed immunotherapies and targeted therapies have mainly replaced chemotherapy for treatment of patients with metastatic and nonresectable melanoma. These new drugs have got improved the prognosis for most patients, but GPs need to be aware of their unique toxicities. Over the past few years there have been major advances in the systemic therapeutic choices for sufferers with metastatic or unresectable melanoma.It’s been popular in Europe for quite some time. We anticipate demand to be huge, despite the higher price, that may drive revenues. The continuing adoption of premium-priced sclerotherapy agents will contribute to a market growth averaging almost 22 % each year through 2015. Millennium Analysis Group’s US Marketplaces for Varicose Vein Treatment Devices 2011 survey includes procedure, average selling price and revenue info for endovenous ablation gadgets, surgical stripping devices, phlebectomy sclerotherapy and devices brokers in the United States.

3SBio obtains ex-China global rights to Apexigen’s anti-TNF mAb technology 3SBio Inc., , a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it offers acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody technology.